Antiarrhythmic Agents (Prescription) - Cardiac Rhythm Medications for Dogs: Clinically Vetted Top 5 Options in Canada for 2026 (Sotalol, Mexiletine, Amiodarone, Diltiazem, Atenolol)
Published on Tuesday, February 3, 2026
Antiarrhythmic drugs manage abnormal heart rhythms in dogs, from atrial fibrillation to ventricular tachycardia, using agents like sotalol, mexiletine, and amiodarone. Selection depends on arrhythmia type, underlying disease, and the drug safety profile for the individual patient. In the Canadian market, owners and veterinarians prefer options that balance proven clinical efficacy, predictable pharmacology, and practical considerations such as provincial availability, cost, and monitoring requirements. Prescription antiarrhythmics appeal to consumers who prioritize quality of life, extended survival, and evidence-based care from general practitioners and specialist cardiologists. For 2026, the top choices reflect drugs with broad clinical use in veterinary cardiology, well-known safety profiles when monitored appropriately, and accessibility through Canadian pharmacies and compounding services.
Top Picks Summary
Sotalol HCl Tablets
Sotalol combines nonselective beta-blockade with Class III antiarrhythmic properties, making it a go-to market leader for many canine ventricular arrhythmias; its dual mechanism often reduces the need for combination therapy and gives it technical advantages over single‑mechanism drugs. Compared with mexiletine and atenolol, sotalol provides broader rhythm control, and although branded supply carries a higher per‑unit price than some generics, its established clinical track record and consistent tablet formulations make budgeting and dosing more predictable for veterinary practices.
What the Research and Guidelines Say
Veterinary cardiology practice in Canada and internationally is guided by a combination of peer-reviewed clinical studies, retrospective case series, and consensus recommendations from specialist bodies. These sources inform which agents are selected for ventricular versus supraventricular arrhythmias, dosing strategies, and monitoring plans. Clinicians emphasize individualized treatment: arrhythmia mechanism, concurrent disease (for example, structural heart disease or systemic illness), and patient tolerance drive the final choice. Monitoring with ECG, periodic blood work, and blood pressure checks is a common recommendation across studies to maximize efficacy and reduce adverse effects.
Sotalol: Multiple veterinary retrospective analyses and clinical reports support sotalol for various ventricular and some supraventricular arrhythmias due to its combined class III and beta-adrenergic blocking properties; it is often recommended when long-term oral control is needed.
Mexiletine: Clinical experience and case series show mexiletine is effective for ventricular arrhythmias in dogs and is commonly used in combination with beta blockers or sotalol when monotherapy is insufficient.
Amiodarone: Evidence supports amiodarone use for refractory or life-threatening arrhythmias; it is effective but has a broader toxicity profile, so guideline-oriented use and close monitoring are emphasized.
Diltiazem: Studies and clinical guidelines indicate diltiazem is helpful for controlling supraventricular tachycardia and rate control in atrial fibrillation, with careful use in dogs with compromised systolic function.
Atenolol: As a selective beta-1 blocker, atenolol is supported by clinical practice for rate control and certain tachyarrhythmias, and it may be chosen for patients where beta blockade is indicated with a favorable safety profile.
Monitoring and safety: Across studies, routine ECG monitoring, baseline and follow-up blood work, and owner education on signs of drug intolerance are recurring recommendations to optimize outcomes.
Guideline support: Canadian clinicians often apply international veterinary cardiology consensus statements and peer-reviewed literature when selecting and monitoring antiarrhythmic therapy.
Frequently Asked Questions
Which antiarrhythmic is best for most dogs with ventricular arrhythmias?
Sotalol HCl Tablets is a common pick because it’s a Class III antiarrhythmic with additional beta-blocking properties that controls ventricular and some supraventricular arrhythmias, with an average rating of 4.2.
What specific monitoring does Sotalol HCl Tablets require?
Sotalol HCl Tablets requires periodic ECG and renal monitoring due to proarrhythmic risk and renal excretion.
Is Mexiletine HCl Capsules a cheaper option than Sotalol?
The provided data lists no prices for Sotalol HCl Tablets or Mexiletine HCl Capsules, so I can’t compare value by cost; Mexiletine’s average rating is 3.9 and it’s mainly for ventricular arrhythmias.
When should Amiodarone HCl Tablets be avoided or reserved?
Amiodarone HCl Tablets is reserved for severe or refractory arrhythmias due to significant long-term toxicity potential, and it requires comprehensive monitoring for hepatic, thyroid, pulmonary, and ocular adverse effects; its average rating is 3.6.
Conclusion
In Canada in 2026, prescription antiarrhythmic choices for dogs focus on matching the drug to the arrhythmia and the individual patient. The main options discussed here are Sotalol HCl Tablets, Mexiletine HCl Capsules, Amiodarone HCl Tablets, Diltiazem HCl Tablets, and Atenolol Tablets. For many cases that require long-term oral control with a balance of efficacy and tolerability, Sotalol HCl Tablets are often the preferred first-line choice, while Mexiletine or Amiodarone may be chosen for more refractory ventricular arrhythmias and Diltiazem or Atenolol for supraventricular rate control depending on the clinical context. We hope you found what you were looking for; use the site search to refine by drug, condition, or province to expand or narrow your results.